Hemolytic anemia screening: Difference between revisions
(Created page with "__NOTOC__ {{Hemolytic anemia}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Ref...") |
|||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hemolytic anemia}} | |||
{{CMG}}; {{shyam}} | |||
==Overview== | |||
There is no major role for screening for hemolytic anemia. In some cases, testing for [[Glucose-6-phosphate dehydrogenase deficiency|G6PD deficiency]] can be done if a patient will be receiving medications that are known to precipitate [[oxidative stress]]. | |||
==Screening== | |||
In some cases, screening for [[glucose-6-phosphate dehydrogenase]] (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. [[Primaquine]], [[sulfa drugs]], and [[Fava bean|fava beans]] can trigger hemolytic crises in the setting of [[Glucose-6-phosphate dehydrogenase deficiency|G6PD deficiency]].<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> [[Rasburicase]] has also been shown to trigger [[hemolytic]] episodes, so G6PD screening is important prior to administration of [[rasburicase]].<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Hematology]] | ||
{{WS}} | |||
{{WH}} | |||
Latest revision as of 18:53, 30 October 2017
|
Hemolytic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemolytic anemia screening On the Web |
|
American Roentgen Ray Society Images of Hemolytic anemia screening |
|
Risk calculators and risk factors for Hemolytic anemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Shyam Patel [2]
Overview
There is no major role for screening for hemolytic anemia. In some cases, testing for G6PD deficiency can be done if a patient will be receiving medications that are known to precipitate oxidative stress.
Screening
In some cases, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.[1] Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.[1]
References
- ↑ 1.0 1.1 Luzzatto L, Seneca E (2014). "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications". Br J Haematol. 164 (4): 469–80. doi:10.1111/bjh.12665. PMC 4153881. PMID 24372186.